The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Preclinical characterisation of 111In‐DTPA‐trastuzumab
Open accessAbstract
Trastuzumab (Herceptin®) is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), used for metastatic breast cancer treatment. Radiolabelled trastuzumab may have several future applications for diagnostic use. The aim of the present study was to develop clinical grade 111 Indium (111 In) radiolabelled trastuzumab, to evaluate the stability and immunoreactivity of the tracer and to perform a biodistribution study in human tumour‐bearing mice. Trastuzumab was radiolabelled with 111 In using DTPA as a chelator. 111 In‐DTPA‐trastuzumab (labelling yield 92.3±2.3%, radiochemical purity 97.0±1.5%) is stable in PBS when stored at 4°C for more than 14 days. The immunoreactive fraction determined by cell‐binding assays, using the HER2‐overexpressing human ovarian SK‐OV‐3 tumour cell line, was 0.87±0.06. Biodistribution and tumour targeting were studied in HER2 receptor‐positive and ‐negative tumour‐bearing athymic mice. The HER2‐positive tumour showed (9.77±1.14% injected dose per gram (ID g−1)) substantial uptake of the labelled antibody already after 5 h. The difference in uptake between HER2‐positive versus ‐negative tumours was even more pronounced 3 days after injection (16.30±0.64% ID g−1), and was visualised by radioimmunoscintigraphy. Liver, spleen and kidney showed marked tracer uptake. In summary, trastuzumab can be efficiently radiolabelled with 111 In with high labelling yields and high stability. 111 In‐DTPA‐trastuzumab selectively binds to the human HER2 receptor both in vitro and in vivo in animals. Therefore, 111 In‐DTPA‐trastuzumab appears suitable for clinical use. British Journal of Pharmacology (2004) 143, 99–106. doi:10.1038/sj.bjp.0705915
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cited by
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
Self-citationIn Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313
Self-citationPerik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
Self-citation
Metadata
- Authors
- Lub‐de Hooge, M. N., Kosterink, J. G. W., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J. H., de Jong, S., Jager, P. L., & de Vries, E. G. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 143
- Issue
- 1
- Pages
- 99-106
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1982322665
- Cited by
- 176
- References
- 1
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical characterisation of 111In‐DTPA‐trastuzumab. https://app.cochat.ai/papers/10.1038/sj.bjp.0705915
- The paper
- Lub‐de Hooge, M. N., Kosterink, J. G. W., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J. H., de Jong, S., Jager, P. L., & de Vries, E. G. E. (2004). Preclinical characterisation of 111In‐DTPA‐trastuzumab. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.